KR101336094B1 - Functional food composition for improving skin condition and preparation method thereof - Google Patents

Abstract

The present invention relates to a health functional food composition for improving skin diseases, and a method of manufacturing the same, and more particularly, to a health functional food composition for improving skin diseases, including extracts of Macmundong, ginseng, Schisandra chinensis and Estuary. . Through the present invention, improves the moisturizing power of dry skin, improve atopic symptoms, improve allergy symptoms, improve wrinkles, improve skin tone, whitening, itching, improve skin barrier function, improve skin immune function and inflammation symptoms, while excellent safety and side effects It is possible to provide a health functional food composition for improving skin diseases.

Description

Functional food composition for improving skin condition and preparation method

The present invention relates to a health functional food composition for improving skin diseases, and a method of manufacturing the same, and more particularly, to a health functional food composition for improving skin diseases, including extracts of Macmundong, ginseng, Schisandra chinensis and Estuary. .

The skin of the human body is an indispensable organ for the maintenance of life, which physically and chemically protects the body from extraterrestrial and performs the biochemical functions necessary for metabolism of the whole body. Relatively common skin diseases include atopic dermatitis, contact dermatitis, seborrheic dermatitis, urticaria, athlete's foot, psoriasis, psoriasis, herpes simplex / shingles, dry skin, housewives and acne.

The external causes of such skin diseases include mechanical stimuli such as friction, compression, and bruise, which act directly on the skin from the outside world, as well as animal, vegetable and mineral poisons, other medicines, radiation, heat, cold, or bacteria, filamentous fungi, protozoa And microorganisms such as viruses and skin parasitic animals, and the like, and endogenous diseases include gastrointestinal disorders, liver disease, kidney disease, metabolic disorders, blood diseases, visceral tumors, and endocrine disorders. Hereditary skin diseases, birthmarks, birthmarks and the like are caused by genes and are included in endogenous skin diseases.

Among skin diseases, in particular, atopic dermatitis is a representative skin disease in people with atopic dermatitis, and is one of chronic skin diseases commonly referred to as febrile fever and recurrent chronic dermatitis with severe pruritus. In recent decades, the prevalence of atopic dermatitis continues to increase due to the increase in airborne allergens due to environmental pollution and the increase in conditions for forming dry skin. It is known that% suffer from this dermatitis. Atopic dermatitis is a chronic relapsing dermatitis that occurs mainly in infants and young children and lasts to adulthood. It is a skin disease with severe pruritus and dry skin, erythema, edema, and exudation. According to a study on the prevalence of atopic dermatitis in Korea, 28.22% reported the prevalence of atopic dermatitis in children, and another study reported the subjective prevalence of adult atopic dermatitis as about 3.09%. Its main symptoms are itching and dry skin, and its immunological properties may lead to other allergic diseases such as urticaria, asthma, allergic rhinitis, and allergic conjunctivitis.

In addition, aging of cells is a physiological natural phenomenon, and the period of regeneration of skin cells, which are the basic units constituting the skin, is not normal, and the regeneration period becomes longer. It progresses as it begins to wrinkle. Currently, surgery, ointment, and vitamin C therapy are used to restore the skin caused by aging, but it is not enough to maintain the long and tender skin.

Methods for improving or treating such atopic skin diseases include methods for improving skin dryness symptoms, using immunomodulators that inhibit the production of IgE, using antibacterial and / or anti-inflammatory components, itching There is a method to improve the and the like and a method of combining two or more of these is also known. In addition, steroids are widely used in the treatment of skin diseases including atopic dermatitis, inflammatory dermatitis, etc. However, steroids can cause various side effects such as decreased immune function, thinning or atrophy of the skin, and flushing. Serious side effects have been reported, such as steroid acne, steroid skin (skin atrophy, capillary enlargement, purpura), steroid injections, perioral dermatitis, hairyness, pigment loss, ancestors, bullous dermatitis, skin bleeding, etc. have.

Several years ago, anti-aging and skin-improving agents using natural products have been developed, but some of them have a function of inhibiting androgen (androgen), which is a male hormone, and a skin-improving effect on sebum secretion. It does not provide a practical effect as a treatment for the skin. Recently, medical skin care (medical skin care), a combination of medical treatment and skin care skin treatment method has been developed for the skin treatment not only in Korea, but also in the United States, Europe, Japan, etc. In addition to improving acne, blemishes and freckles, many skin diseases are still a major cause of poor quality of life without being overcome.

In this regard, there are known examples of extracts of active ingredients of herbal medicines known to have effects such as skin improvement, moisturization, wrinkle improvement, and the like, and have been developed as skin improvers. For example, Korean Patent Publication No. 10-2010-0101269 and Korean Patent Registration No. 10-0962587 provide a skin improvement composition using a wide variety of plant materials, both of which are characterized by the fermentation method, It is not seen that the skin improvement effect of a single or mixed extract of a particular plant is excellent. In addition, Korean Patent Registration No. 10-0991399, Korean Patent Registration No. 10-0999870, Korean Patent Registration No. 10-0987563, etc., describes a composition for improving atopic dermatitis including a wide variety of plant extracts.

However, most of these techniques only relieve itching and inflammation, so the therapeutic effect is insignificant, and the practical application of the present invention is limited. The aforementioned methods for treating or improving atopic dermatitis aim to alleviate or improve one or two symptoms, such as itching or anti-inflammatory, and may have serious side effects such as complex infections. It is also happening. In addition, those containing various herbal medicines are mainly oral medications or health supplements may be beneficial to relieve atopic dermatitis, but other side effects may occur. In other words, when using a variety of natural herbal ingredients, the way to improve the side effects may be different from each other, the timing of improvement is different, and the relapse prevention effect may also be different. Therefore, there is a need for a herbal composition that has excellent effects and has no skin irritation and is safely prepared.

1. Korea Patent Registration No. 10-0991399 2. Korean Patent No. 10-0999870 3. Korea Patent Registration No. 10-0987563

Improved moisturizing ability of dry skin, atopic symptoms improvement, allergy symptoms improvement, wrinkle improvement, skin tone improvement, whitening, itching improvement, skin barrier function improvement, skin immune function improvement and inflammatory symptoms improvement but excellent safety and side effects The present invention provides a health functional food composition for reducing skin diseases and a method of manufacturing the same.

According to an aspect of the present invention, there is provided a health functional food composition for improving skin diseases comprising a mixed extract of Macmundong, ginseng, Schisandra chinensis and Eochocho.

According to an aspect of the present invention, the extract of the health functional food composition for improving skin diseases is selected from crude extract, dried extract of crude extract, concentrate of crude extract, fraction of crude extract, dried fraction and concentrate of fraction It is characterized by the above.

According to one aspect of the present invention, the extract of McMung-Dong, Ginseng, Schisandra chinensis and Eochochocho of the health functional food composition for improving skin diseases is the weight ratio of Macmundong: Ginseng: Schisandra chinensis: Echochocho to 1-8: 1-4: 1-4. : It is characterized by 1-8.

According to an aspect of the present invention, the extracts of McMun-Dong, Ginseng, Schisandra chinensis and Eochochocho of the health functional food composition for improving skin diseases are characterized in that the weight ratio of McMoon-Dong: Ginseng: Schisandra chinensis: Echochocho is 1: 1: 1: 1. .

According to an aspect of the present invention, the extract of the health functional food composition for improving skin diseases is characterized in that the extract is available as a solvent selected from water, lower alcohols having 1 to 4 carbon atoms or a mixed solvent thereof.

According to an aspect of the present invention, the health functional food composition for improving skin diseases further comprises at least one of a carrier, a diluent, an excipient and an additive in the extract, tablets, pills, powders, granules, powders, capsules and liquids. It is characterized by being formulated as one selected from the group consisting of formulations.

According to an aspect of the present invention, there is provided a method for producing a health functional food composition for improving skin diseases, comprising the step of extracting by adding a solvent to extract the ganmundong, ginseng, Schisandra chinensis and Eochocho and concentrating the extract. .

According to one aspect of the invention, the step of obtaining an extract of the method for producing a health functional food composition for improving skin diseases is extracted by adding a solvent of 5 to 20 times the weight of the total weight of ganmundong, ginseng, Schisandra chinensis and Echochocho It features.

According to one aspect of the invention, the step of obtaining the extract of the method for producing a health functional food composition for improving skin diseases is characterized in that it is performed for 1 hour to 10 hours at 80 ℃ to 120 ℃.

According to one aspect of the invention, the step of concentrating the manufacturing method of the health functional food composition for improving skin disease is filtering the extract, concentrating the filtered extract under reduced pressure, drying the concentrated extract And pulverizing the dried concentrate to form a powder.

The health functional food composition for improving skin diseases according to the present invention improves the moisturizing ability of dry skin, improves atopic dermatitis symptoms, improves allergic symptoms, improves wrinkles, improves skin tone, improves whitening, itching, improves skin barrier function, improves skin immune function and inflammation. Excellent symptom improvement but safety and fewer side effects.

The method for producing a health functional food composition for improving skin diseases according to the present invention improves the moisturizing ability of dry skin, improves atopic symptoms, improves allergic symptoms, improves wrinkles, improves skin tone, improves whitening, itching, improves skin barrier function, and improves skin immune function. And it provides an excellent functional food composition for improving skin diseases with excellent safety and excellent safety and less side effects.

1 is a result of cell culture by treating Example 1 and Comparative Example by concentration. (a) is a comparative example, (b) is the result of having processed Example 1.
2 is a graph showing the tyrosinase inhibitory activity when Example 1 and Comparative Example were treated by concentration. (a) is a comparative example, (b) is the result of having processed Example 1.
3 is a western blotting photograph showing the expression levels of filaggrin and SPT when treated according to the concentration of Example 1 and Comparative Examples. (a) is a comparative example, (b) is the result of having processed Example 1.
FIG. 4 is a graph showing relatively the expression levels of filaggrin and SPT when Example 1 and Comparative Example are treated by concentration. (a) is a comparative example, (b) is the result of having processed Example 1.
5 is a western blotting photograph showing the expression level of COX-2 and AP-1 when Example 1 and Comparative Example were treated by concentration. (a) is a comparative example, (b) is the result of having processed Example 1.
FIG. 6 is a graph showing relatively the expression level of COX-2 and AP-1 when Example 1 and Comparative Example were treated by concentration. (a) is a comparative example, (b) is the result of having processed Example 1.
Figure 7 is a photograph showing the skin condition of the animals in each group at the beginning of the experiment in the animal experiment causing atopic dermatitis. A is control (not administered), B is comparative group (comparative administration), C is experimental group (Example 1 administration).
Figure 8 is a photograph showing the skin condition of the animals in each group of the first week of administration in the animal experiments causing atopic dermatitis. A is control (not administered), B is comparative group (comparative administration), C is experimental group (Example 1 administration).
Figure 9 is a photograph showing the skin condition of animals in each group at the 2nd week of administration in the animal experiments inducing atopic dermatitis. A is control (not administered), B is comparative group (comparative administration), C is experimental group (Example 1 administration).
10 is a photograph showing the skin condition of animals in each group at the 3rd week of administration in an animal experiment inducing atopic dermatitis. A is control (not administered), B is comparative group (comparative administration), C is experimental group (Example 1 administration).
11 is a photograph showing the skin condition of animals in each group at the 4th week of administration in an animal experiment inducing atopic dermatitis. A is control (not administered), B is comparative group (comparative administration), C is experimental group (Example 1 administration).
12 is a graph showing the score of the degree of skin inflammation according to the administration period in the animal experiments inducing atopic dermatitis.
FIG. 13 is a graph showing the amount of immunoglobulin E (IgE) according to the administration period in animal experiments causing atopic dermatitis.
14 is a graph showing the amount of interleukin (IL) -4 in animal experiments that induce atopic dermatitis.
FIG. 15 is a graph showing the amount of interleukin (IL) -5 in animal experiments causing atopic dermatitis.
Figure 16 is a graph showing the amount of interleukin (IL) -6 in animal experiments causing atopic dermatitis.
Figure 17 is a graph showing the amount of immunoglobulin M (IgM) in animal experiments causing atopic dermatitis.
Figure 18 is a graph showing the amount of immunoglobulin G1 (IgG1) 6 in animal experiments causing atopic dermatitis.
Figure 19 is a graph showing the amount of interferon gamma (IFN-γ) in animal experiments causing atopic dermatitis.

The present invention for achieving the above-described object provides a health functional food composition for improving skin diseases, including the extract of the mammundong, ginseng, Schisandra chinensis and Eochochocho and a method for producing the same. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention will now be described in detail with reference to the accompanying drawings.

According to the present invention, there is provided a health functional food composition for improving skin diseases, including extracts of mammundong, ginseng, Schisandra chinensis and Echochocho.

Limoope platyphyllla is a lump of lobular vegetation and related plants and grows in the shade of evergreens of the monocotyledonous lily. The taste is sweet and the nature is cold. Enter the lungs, stomach and heart. It is mainly used as anti-inflammatory, tonic, cough, expectorant and cardiac. The muscle mass of the pulmonary sinus contains various types of steroidal saponins, and its aglycone is ruscogenin. It also contains beta sitosterol (β-sitosterol), stigmasterol (stigmasterol), and beta sitosterol beta diglucoside (β-sitosterol-β-d-glucoside). The fruit of the pulses contains an opioside called kaempferol-3-glucogalactoside. Macmundong lowers blood sugar and is known to have antimicrobial activity against white Pococcus and E. coli.

Ginseng (Panax ginseng) is the root of ginseng, a genus of ginseng and ginseng plant, and is known to be effective in reinforcing the ginseng roots, encouraging the spleen and the intestines, quenching thirst, and calming the mind. In addition, modern pharmacological effects such as central nervous system control, immune enhancement, heart rate, blood sugar lowering effect is said.

Schisandra chinensis Baillon is a fruit of Schizandra chinensis Baillon tree, about 1cm in diameter, dark red. It has five flavors: sweet, sour, bitter, salty, and spicy, with the strongest of them. Schisandrarin, gomisin, citric acid, citric acid, citric acid and other ingredients, such as strong to strengthen the heart, lower blood pressure and increase immunity to use as a tonic, strong lung function and antitussive, expectorant action, cough or thirst It has a therapeutic effect against. Schisandra chinensis has long been used in herbal medicine as a raw material of medicinal herbs and has the effects of astringent, nourishment, tonic, ginhae medicine, haejudok, thirsty, convergent shovel, ripe ginjin, bosin dyed heart. Human stability with ingestion has already been confirmed.

Houttuynia Cordata is a perennial herb belonging to over three hundred and over, and is composed of medicinal herb in Korean encyclopedia. It is called as medicinal herb, Chinese herb, medicinal herb, and there are about 30 kinds of tinnitus. Eoseongcho has an antibacterial effect, and is known to have anti-inflammatory, analgesic, and tissue regeneration effects. In oriental medicine, it is called a blood detoxifying agent by 'clogging blood and eliminating poison'. It is used for the treatment of bleeding, decolonization, species, paralysis, pneumonia, eczema, eczema, otitis media and hypertension. It has strong antibacterial effect. In fact, it is known that antiviral activity against katharrh cocci and influenza type A is excellent, as well as diuretic, cardiovascular, hypertension and capillary strengthening.

The pulsed dong, ginseng, Schisandra chinensis and fish herb may be extracted as a whole, or may be extracted by cutting to a suitable size (for example, 3 to 20 cm in length, schisandra chinensis), or pulverized or ground. Generally, in order to extract the effective ingredient most effectively, it is preferable to break it and extract it.

Extraction method of the extract is hot water extraction method, heat extraction method, reflux cooling extraction method, ultrasonic extraction method, supercritical extraction method using carbon dioxide, low temperature compression method, extraction method using an ultrafiltration membrane having a constant molecular weight cut-off value, by various chromatography It can be extracted by various known methods such as extraction method.

The extract may be prepared by separately extracting each component and mixing, or after mixing the medicinal herbs. That is, it is also possible to extract and mix the medicine (mixed extraction), it is also possible to mix the extract after extracting for each component, it is preferable in terms of manufacturing efficiency and economics to mix and extract the medicine.

The extract used in the present invention is characterized in that at least one selected from crude extract, dried crude extract, concentrate of crude extract, fraction of crude extract, dried fraction and concentrate of fraction. Although not limited to the above-mentioned forms, crude extracts, dried crude extracts, crude extract concentrates, crude extract fractions, dried fractions or concentrates of fractions have excellent skin-improving effects, and the preparation and storage of extracts And convenience in handling and formulation formulation.

The extract used in the present invention may use all of the extracts obtained in each step, but the content for achieving the desired effect varies depending on which step the extract is applied to the composition according to the present invention. For example, when using the crude extract directly obtained by filtration after solvent extraction, it is preferable to contain 0.05 to 80.0% by weight relative to the total weight of the composition. If the content is less than 0.05% by weight, the desired skin improvement effect of the present invention may not be sufficient. On the contrary, if the content is more than 80.0% by weight, the effect of increasing the content is not increased, which is not economical and the stability of the product is lowered. Can be. In addition, in the case of dried products or concentrates in which the content of the active ingredient in the extract is selectively increased through a reduced pressure concentrator and a lyophilizer, the preferred content is in the range of 0.001 to 20.0% by weight based on the total weight of the composition.

Extracts used in the present invention can be obtained using a variety of extraction methods known in the art, and includes not only crude extracts by a solvent, but also extracts obtained through conventional purification processes. Obtained by various additional purification methods, such as separation using ultrafiltration membranes having a constant molecular weight cut-off value, separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity). Fractions are also included in the extract of the present invention. The extract of the present invention can be prepared in powder form by an additional process such as vacuum distillation and freeze-drying or spray-drying.

Improvement of the skin of the pharmaceutical composition for improving skin of the present invention improves the moisturizing power of dry skin, improves atopic dermatitis symptoms, improves allergic symptoms, improves wrinkles, improves skin tone, improves whitening, itching, improves skin barrier function, improves skin immune function and inflammation symptoms At least one of the improvements.

Extracts of McMoon-Dong, Ginseng, Schisandra chinensis and Eochochocho of the health functional food composition for improving skin diseases according to the present invention are the weight ratio of McMoon-Dong: Ginseng: Schisandra chinensis: Echochocho to 1-8: 1-4: 1-4: 1-8 It is characterized by (based on the dry weight of the raw material). Although it is not limited to the mixing ratio of ginmundong, ginseng, schisandra chinensis and fish herb, it is preferable to mix and composition in the said range in order to show the more excellent skin improvement effect. Among them, the weight ratio of Macmundong: Ginseng: Schisandra chinensis: Echoseongcho is 1: 1: 1: 2 (based on the dry weight of the raw material), which is most preferable because of excellent skin improvement effect. If it is in the range corresponding to the said ratio, each extract may be prepared by mixing each corresponding ratio.

The extract of the health functional food composition for improving skin diseases according to the present invention is characterized in that the extract is available as a solvent selected from water, a lower alcohol having 1 to 4 carbon atoms or a mixed solvent thereof. In principle, the extract is not limited to the type of solvent, but a solvent selected from water, a lower alcohol having 1 to 4 carbon atoms or a mixed solvent thereof is preferable, and among these, an extract extracted using purified water is effective and formulation stability of the present invention. It is preferable because it is excellent in terms.

Extract of the dietary supplement composition for improving skin diseases according to the present invention further comprises at least one of a carrier, a diluent, an excipient and an additive selected from the group consisting of tablets, pills, powders, granules, powders, capsules and liquid formulations. Characterized in one. Foods to which the extract of the present invention can be added include various foods, powders, granules, tablets, capsules, syrups, beverages, gums, teas, vitamin complexes, and health functional foods.

As additives that may be further included in the present invention, natural carbohydrates, flavors, nutrients, vitamins, minerals (electrolytes), flavors (synthetic flavors, natural flavors, etc.), colorants, fillers (cheese, chocolate, etc.), One or more components selected from the group consisting of fact acids and salts thereof, alginic acids and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, antioxidants, glycerin, alcohols, carbonating agents and pulp .

Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the flavoring agent, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used.

In addition to the above, the composition according to the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic and natural flavors, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, alginic acid and Salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like. In addition, the composition according to the present invention may contain fruit flesh for the production of natural fruit juices and vegetable drinks. These components may be used independently or in combination.

Specific examples of the carrier, excipient, diluent, and additives include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, erythritol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium phosphate, calcium Silicates, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, polyvinylpyrrolidone, methylcellulose, water, sugar syrup, methylcellulose, methyl hydroxy benzoate, propyl hydroxy benzoate, talc, magnesium stearate And at least one selected from the group consisting of mineral oils.

When formulating a health functional food composition for skin disease improvement according to the present invention is prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc. that are commonly used.

The content of the extract according to the present invention as an active ingredient in the above-described formulations can be appropriately adjusted according to the use form and purpose, patient condition, type of symptom and severity, etc. 0.01 to 50% by weight, but is not limited thereto.

The dosage of the extract-containing composition of the present invention may vary depending on the age, weight, sex, dosage form, health condition and degree of disease of the patient, and once or several times a day at regular intervals according to the judgment of the doctor or pharmacist. It may be administered in divided doses. For example, the daily dosage may be 0.5 to 500 mg / kg, preferably 1 to 300 mg / kg, based on the active ingredient content. The above dosages are illustrative of the average case and may be high or low depending on individual differences. If the daily dose of the mixed extract-containing composition of the present invention is less than the dosage, it may not be possible to obtain a significant effect. Can be.

According to the present invention, it provides a method for producing a health functional food composition for improving skin diseases comprising the step of obtaining the extract by extracting by adding a solvent to myeongmundong, ginseng, Schisandra chinensis and Eochocho. The extraction method may be performed by a conventional method, as described above in the extract.

Obtaining the extract of the method for producing a health functional food composition for improving skin diseases according to the present invention is characterized in that the extract by adding a solvent of 5 to 20 times the weight of the total weight of ganmundong, ginseng, Schisandra chinensis and eoseongcho. Although not limited to the amount of the solvent, when the amount of the solvent is higher than the above, the concentration of the active ingredient is low or the energy or time required for extraction, and if less than the final extract compared to the initial material input Yield can be reduced.

Obtaining the extract of the method for producing a health functional food composition for improving skin diseases according to the present invention is characterized in that it is carried out at 80 ℃ to 120 ℃ for 1 hour to 10 hours. Although not limited to the above time and temperature, it is preferable to perform 1 hour to 10 hours at 80 ° C. to 120 ° C. for substantial dissolution of the active ingredient, and particularly, 3 hours to 5 hours at 95 ° C. to 115 ° C. It is most effective in terms of dissolution of the active ingredient. If the temperature is lower or shorter than the temperature, the actual elution of the active ingredient is reduced. If the temperature is higher or longer than the temperature, the time or efficiency of the extraction process is reduced, the active ingredient is destroyed, or undesirable components are mixed. Or taste may change.

Concentrating the manufacturing method of the health functional food composition for improving skin diseases according to the present invention more specifically, the step of filtering the extract, condensing the filtered extract under reduced pressure, drying the concentrated extract and And pulverizing the dried concentrate to powder.

The method of filtering, concentrating, drying and pulverizing the extract is not limited to a specific method as long as it is a filtration, concentration, drying and pulverization method that can be commonly applied to the extract. More preferably, in the filtration process, a filter of a suitable size capable of removing impurities while containing the extracted active ingredient may be included in the filtrate, and a series of pulverization in filtration may be performed at 60 ° C. or lower to prevent destruction of the active ingredient. It is preferable to proceed.

Therefore, the extract used in the present invention can preferably be obtained by the following method. First, add a certain amount of water to each of the mungmundong, ginseng, Schisandra chinensis and Eoseongcho and then extract it while boiling for about 1 hour to 10 hours under reflux, and then filtrate the filtrate and adjust the total amount by adding water, and then at 1 low temperature. The precipitate can be obtained by performing membrane filtration on the resulting precipitate left for 1 to 12 days.

In addition, for the sufficient extraction of the active ingredient present in the herbal medicine, by adding the solvent once again to the herbal medicine extracted once by the above process may be added to the extraction process again. In this case, it is more efficient and preferable if the first and second extracts are mixed and filtered and concentrated at the same time.

Hereinafter, the present invention will be described in more detail with reference to Examples. It should be understood, however, that these examples are for illustrative purposes only and are not to be construed as limiting the scope of the present invention.

Example 1 according to the present invention was prepared through the following process.

Megmundong, ginseng, Schisandra chinensis and Eochocho were purchased on the market, 40g of Macmundong, 40g of Ginseng, 40g of Schisandra chinensis and 80g of Echochocho were added to an extractor, 2.7L of purified water was added thereto, and extracted by heating at 112 ° C for 3 hours to obtain 1.5L of extract.

Comparative Example was prepared in the same manner as in Preparation of Example 1, except that the fish paste was not added.

Example 1 Comparative Example Macmundong (g) 40 40 Ginseng (g) 40 40 Schisandra (g) 40 40 Goshencho (g) 80 -

As a result of measuring the density | concentration of the hot water liquid with a solid content measuring device, the density | concentration of the extract of Example 1 was 10.3%, and the density | concentration of the extract of the comparative example was 9.8%.

Each extract obtained above was filtered using a filter cloth and lyophilized using a lyophilizer, which was then stored and used at 4 ° C.

[ Test Example ]

1. Preparation and Experiment Method

1) Preparation of experimental animals

8 week-old NC / Nga atopy mice were fed from a central laboratory animal and fed solid feed and water until the day of the experiment. Room temperature 22 ± 2 ℃, relative humidity 50-55%, illuminance 200 lux Adapted to the laboratory environment for 1 week while keeping the lights off at 20 o'clock) and used in the experiment.

2) Preparation of Reagents

The reagents used in this experiment were diethyl pyrocarbonate (DEPC), ammonium chloride (NH ₄ Cl), potassium bicarbonate (KHCO ₃ ), ethylenediaminetetraacetate (Na ₂ EDTA), and complete adjuvant (complete). adjuvant, chloroform, collagenase IV, medium RPMI-1640, isopropanol, erythrocyte ACK lysis solution, ethidium bromide (EtBr), Dulbecco's phosphate buffered saline (Dulbecco's phosphate buffered saline (D-PBS), Dulbecco's minimum essential medium (DMEM), formaldehyde, magnesium chloride (magnesium chloride, MgCl ₂ ) and agarose are available from Sigma Corporation (USA). Products, fetal bovine serum (FBS) is a Gibco BRL (USA) product, RNase inhibitor, RNase inhibitor, Taq polymerase, random primer, deoxynucleotide triphosphate , dNTP) and Moloney murine leukemia virus reverse transcriptase (M-MLV RT) uses Promega (USA) products such as interleukin-4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL-6) and interferongamma (IFN- γ) ELISA kit from BD (USA), immunoglobulin E (IgE), immunoglobulin M (IgM) and immunoglobulin G1 (IgG1) ELISA kit of Goma Biotech (Korea), RNAzolB is invitrogen (USA) was used, and other used reagents were purchased from Duksan (Korea).

3) culturing human keratinocyte cell lines, Examples and Comparative example  process

Human kerationocyte HaCaT cell line used in the experiment was prepared in 10% fetal bovine serum (FBS; Gibco CO., USA), 1% penicilin-streptomycin (Gibco Co., USA) in DMEM medium. ) Was used to incubate at 37 ℃, 5% CO ₂ conditions. Cells were incubated in a 75 mm plate until reaching a confluency of about 80%.

Diluted in the Comparative Example and Example 1 provided in the respective distilled water to make a stock of 1% (w / v), the processing is in the final concentration of the medium to be 0.01, 0.02, 0.05, 0.1% in the CO ₂ incubator 24 Incubated for hours. As a control, the same method was used except that the control was incubated in a medium without addition of Comparative Example and Example 1.

4) Cell viability test Cell viability test )

Cell viability test was conducted using a cell counting assay. The extract samples (Example 1 and Comparative Example) prepared above were treated for each concentration to remove the treated medium and reagents after 24 hours of incubation. After treatment with 200 μl of trypsin-EDTA buffer (Trypsin-EDTA buffer, TE buffer) and left in the incubator for 2-3 minutes. After adding 1.8 ml of phosphate buffered saline, the cells were dropped from the plate, 10 μl of Trypan blue and 10 μl of cell solution were mixed well, and reacted at room temperature for 3 to 4 minutes.

After the cover glass was placed on the hemacytometer, 10 µl of the reactant was injected into the gap between the hemacytometer and the cover glass, and the number of unstained and stained cells was measured using a microscope.

5) Tairosineiz  Inhibitory activity ( Tyrosinase inhibition activity ) analysis

After taking the cell extract treated with each sample, 100 μl of cell extract, 20 μl of 500U tyrosinase and 80 μl of 1.5 mM L-DOPA were added to a 96 well plate and reacted at 37 ° C. for 10 minutes, and then at 450 nm. Absorbance was measured. And phosphate buffered saline (PBS) instead of tyrosinase was added in the same way by measuring the blank value (B) and lysis buffer instead of the sample solution and tyrosinase (C) and PBS (D) as above. After the reaction at 37 ° C. for 10 minutes, the inhibitory activity against tyrosinase was calculated by the following Equation 1 from the measured absorbance at 450 nm.

6) Pillar Green ( Filaggrin ) And Serine palmitoyl  Transferraise ( serine palmitoyl  transferase, SPT ) Expression analysis

To evaluate the expression of Filaggrin, total RNA was extracted from the cells cultured and tested by the above method using Trizol, invitrogen CO., USA, and then one step RNA PCR kit (AMV). According to the method provided by (Takara Bio Inc., Japan), reverse transcription polymerase chain reaction (RT-PCR) analysis was performed. PCR amplification was performed using GeneAmp ^® PCR System 2700 (Applied Biosystems, USA) for 30 seconds of denaturation at 94 ° C, followed by slow cooling at 60 ° C for 30 seconds, and 75 ° C at 72 ° C. During extension by DNA polymerase. The amplification products obtained in the reaction are filaggrin (filaggrin) and β-actin (about 400bp and 300bp, respectively). At this time, the primer for filaggrin was used 5'-GGTAGATAGATCTGGACACTCAGGG-3 'of Bioneer Corporation (Korea), and the expression level was compared using β-actin as the internal control.

To analyze serine palmitoyl transferase (SPT) expression, mRNA levels of SPT were analyzed by RT-PCR according to Dorfman and Lichtenstein's method. Total RNA was extracted from the cells cultured and tested by the above method using trizol, and cDNA was synthesized according to the method provided by First strand cDNA synthesis kit (Fermentas, USA). RT-PCR was performed by PCR mix with a total volume of 20 μl with 1 μl template, 10 μl PCR master mix (Qiagen, USA), 1 μl β-actin and 7 μl distilled water. The PCR conditions were 45 cycles with denature (95 ℃, 15 seconds), annealing, extension (60 ℃, 60 seconds), and the amount of mRNA was amplified due to variation of each template using comparative CT method. In addition, the house keeping gene β-actin was determined as the reference for each gene, and quantification was induced, and each gene in the control sample was determined as a calibrator.

7) protein extraction and COX -2, AP -1 of Western  analysis

In order to evaluate the expression of COX-2 and AP-1, the cells were cultured and tested by the above method, and the protein was extracted by treating lysis buffer. The Lysis buffer was prepared in the following composition; 0.1% Triton X-100, 20 mM Tris-Cl (pH 7.4), 1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM ethylene glycol bis (2-aminoethylether) 4-acetic acid (ethylene glycol bis (2-aminoethyl ether) tetraacetic acid (EGTA), 150 mM sodium chloride (NaCl).

After electrophoresis of 30 µg of protein on a 10% SDS-polyacrylamide gel, the protein was transferred to a nitrocellulose membrane, and the membrane of COX-2, AP-1, and Actin was blocked. Block for 1 hour with solution (diluted skim milk powder in 5% in 1 × TBS-T solution). The primary antibody was reacted at 4 ° C. for 12 hours, and after washing, the secondary antibody was reacted with an ECL western blotting detection system.

8) Inflammatory Experiment

NC / Nga mice were tested for 6 animals per experimental group and 3 animals for each cage. That is, the experiment was carried out by dividing into six cages in 18 NC / Nga mice and 6 control groups provided with water, 6 comparative groups provided with a comparative example, and 6 experimental groups provided with Example 1.

Atopic dermatitis was induced in all of the experimental animals using 1-chloro-2,4-dinitrobenzene (DNCB). First, the back of the NC / Nga mice was epilated and left for 24 hours to heal fine wounds on the skin. 200 μl of 1% DNCB solution (acetone: olive oil = 3: 1) was applied to the back area 4 days before the experiment, and 150 μl of 0.2% DNCB solution was applied to the back area twice a week for 4 weeks from the start date of the experiment to the end date. Induced inflammation.

Experiments were conducted in rats with atopic dermatitis for 4 weeks, during which time the control group was administered only drinking water, and the comparison group was drinking water mixed with a comparative example containing no fish herb, and the experimental group was mixed with Example 1 Provided. Drinking water of the comparison group and the experimental group was provided by adding 150 mg of extract (0.1% dilution) to 150 g of distilled water, which corresponds to the amount of 50 mg of extract per animal.

9) Skin damage measurement

The skin damage of NC / Nga mice was evaluated by clinical visual evaluation method commonly used in atopic dermatitis. The gross evaluation results are the sum of the scores of each of the five categories of erythema, itching and dry skin, edema and escoriation, erosion, and lichenification. As shown. Each of these items was scored by dividing into none (0), weak (1), severity (2), and severe (3).

11) Serum  Interleukin ( IL ) -4,5,6 and Immunoglobulin M ( IgM ), Immunoglobulin G1 (IgG1), Interferongamma ( IFN γ) quantification

Four weeks after the administration of the extract, NC / Nga mice were anesthetized with ethyl ether, and blood was collected by cardiac puncture to separate the serum, and then interlukin (IL) -4, 5, 6 and immunoglobulin in serum. The amount of M (immunoglobulin M, IgM), immunoglobulin G1 (immunoglobulin G1, IgG1), and interferon-gamma (interferon-γ, IFN-γ) were respectively quantified by ELISA kit.

2. Effect of Extracts on Cells

1) Effect on Cell Growth

The effect of the extract according to the invention on the skin cells was evaluated. The results obtained when Example 1 and Comparative Example were added to the culture medium at concentrations of 0, 0.01, 0.02, 0.05 and 0.1%, respectively, are shown in FIG. 1.

As shown in Figure 1, both cases did not have a detrimental effect on cell survival, it was confirmed that the cell growth is well performed without any effect as a control (culture picture of the control group not shown).

2) Tairosineiz ( tyrosinase ) Effect on inhibitory activity

In order to examine the effect of the extract on tyrosinase inhibitory activity, Comparative Example and Example 1 were treated in culture media by 0.01, 0.02, 0.05, and 0.1% concentrations in human keratinocyte HaCaT cells, respectively, and the results are shown in FIG. 2. It was. (a) is the experimental result which processed the comparative example, (b) is the experimental result which processed Example 1.

As shown in FIG. 2, in the comparative example (a), the tyrosinase inhibitory activity tended to decrease as the concentration was increased. In contrast, in Example 1 (b), the tyrosinase inhibitory activity was increased in a concentration-dependent manner.

In other words, it can be seen that by inhibiting the production of melanin and other pigments while inhibiting tyrosinase activity according to Example 1, it is possible to inhibit the production of spots and the like that may be generated during skin aging.

3) Effects on Skin Barrier Regulators

In order to examine the effect of the extract on skin barrier function regulators, Comparative Example and Example 1 were treated by 0.01, 0.02, 0.05 and 0.1% concentrations of filaggrin and serine palmitoyl transferase (SPT), respectively. mRNA expression was analyzed by reverse transcription (RT) PCR, and the results are shown in FIGS. 3 and 4. (a) is the experimental result which processed the comparative example, (b) is the experimental result which processed Example 1.

3 and 4, in Comparative Example (a), the expression level of filaggrin was decreased in a concentration-dependent manner. In Example 1 (b), the expression level of filaggrin was increased in a concentration-dependent manner. Seemed. In addition, the expression level of SPT also appeared to increase temporarily at 0.01% in Comparative Example (a), but showed a decrease in concentration-dependent manner. In Example 1 (b), the expression level increased in concentration and showed the highest expression level at 0.05%. .

Taken together, the comparative example was found to adversely affect the expression of the skin barrier regulator, and when exposed to it, it is judged to be irritating to the skin, but in Example 1, it can be seen that it has a good effect on the expression of the skin barrier regulator. there was. Therefore, it can be seen that Example 1 enhances the function of maintaining the skin's water retention function by increasing the amount of skin barrier regulators, filaggrin and SPT.

4) Effect on skin anti-inflammatory response factors

To investigate the effect of the extract on skin anti-inflammatory response factors, Comparative Example and Example 1 were treated by 0.01, 0.02, 0.05 and 0.1% concentrations, respectively, to express COX-2 and transcription factor of COX-2. Expression of AP-1 was analyzed by western blotting, and the results are shown in FIGS. 5 and 6. (a) is the experimental result which processed the comparative example, (b) is the experimental result which processed Example 1.

As shown in Figure 5 and 6, in Comparative Example (a) except for 0.02% treatment, the expression of COX-2 increased in a concentration-dependent manner, AP-1 also increased the amount of expression as the concentration increases It was. On the other hand, in Example 1 (b) except for 0.02% treatment, the expression of COX-2 decreased in a concentration-dependent manner, AP-1 also decreased significantly as the concentration increased.

Taken together, it can be seen that Example 1 can suppress skin inflammation by reducing skin inflammatory response factors.

3. Evaluation of Skin Inflammation Symptom Improvement Efficacy in Dermatitis Animal Model

The rats causing atopic dermatitis were divided into a control group without adding an extract to drinking water, a comparative group with a comparative example, and an experimental group with Example 1 to evaluate the degree of improvement of the inflammatory symptoms. 7 to 11 are shown. In each photo, A is a control group, B is a comparison group, and C is an animal photograph of the experimental group.

According to the experimental method, when the DNCB was treated in NC / Nga mice, the skin rash began to appear clearly at 4 days after treatment (see FIG. 7). After 1 week of administration, the control group (A) had a severe skin rash, and the control group (B) and the experimental group (C) were also weaker than the control group (A), but it was observed that the skin rash progressed (see FIG. 8). After 2 weeks of administration, the skin rash in the control group (A) became worse, but the symptoms of the skin rash improved slightly in both the control group (B) and the experimental group (C), especially in the experimental group (C). It was confirmed that the degree of improvement is rather high (see FIG. 9). After 3 weeks of administration, the skin rash of the control group (A) did not worsen anymore, but it was seen that the skin rash recovered significantly in the comparison group (B) and the experimental group (C) (see FIG. 10). After 4 weeks of administration, the skin rash of the control group (A) was also slightly improved, and it was observed that the skin rash was restored to almost normal level in the comparison group (B) and the experimental group (C) (see FIG. 11).

The results obtained by scoring the test results (Clinical skin severity score) are shown in FIG. 12. As shown in FIG. 12, two weeks after administration, the skin damage of the control group (B) (3.8) and the experimental group (C) (3.5) was further reduced than the control group (A) (8.5). At 3 weeks of administration, the skin damage of the control group (A) was 9.5, which was slightly worse than that of the 2nd week of administration. I recovered. At week 4, the control group (A) had skin damage of about 6.5 and showed more recovery than at week 3, but the comparison group (B) (1.5) and the experimental group (C) (1.2) were almost normal. Improvements were made. In addition, it can be seen from the initial experimental process that the skin inflammation reduction and recovery in the experimental group (C) appeared early from the beginning, and the degree of recovery is also larger than the experimental group (B).

4. Extracts from dermatitis animal models Inflammatory factor  And Immune factor  Effect on expression

The rats inducing atopic dermatitis were divided into a control group without adding extract to drinking water, a comparative group with a comparative example, and an experimental group with Example 1, and their effects on the expression of various inflammatory and immune factors in serum. Evaluated.

1) Results for Immunoglobulin E (IgE)

Results for immunoglobulin E (IgE) are shown in FIG. 13. Early in the experiment, due to the induction of atopic dermatitis, it can be seen that the levels of immunoglobulins are similar to each other in the control, comparison and experimental groups. IgE production in control serum was continuously increased during 3 weeks of administration but slightly decreased at 4 weeks. Serum IgE production increased rapidly due to dermatitis in the first week and then decreased significantly with time of administration. The IgE production in the experimental group increased sharply due to dermatitis in the first week and then significantly decreased significantly with the administration time (p <0.01). In particular, the experimental group showed the same tendency as the comparative group, but the decrease in IgE production in the serum of the experimental group was greater. Specific values of immunoglobulin IgE for each experimental period are shown in the following table.

0 weeks 1 week 2 weeks 3 weeks 4 weeks Control group (ng / ml) 152.9 ± 12.80 258.4 ± 14.54 286.7 ± 11.14 312.5 ± 16.12 225.4 ± 12.21 Comparative group (ng / ml) 145.9 ± 10.12 214.5 ± 11.87 174.2 ± 10.52 132.2 ± 11.45 105.3 ± 11.02 Experimental group (ng / ml) 161.5 ± 9.89 195.5 ± 10.74 155.1 ± 10.20 122.4 ± 11.31 85.3 ± 9.25

2) Results for Interleukin-4 (IL-4)

Results for interleukin-4 (IL-4) are shown in FIG. 14. As shown in FIG. 14, the control group was 45.25 ± 4.85 pg / ml, the comparison group was 25.12 ± 2.9 pg / ml, and the experimental group was 20.35 ± 3.54 pg / ml. Both the control and experimental groups showed a significant decrease (p <0.01) compared to the control group, and the reduction of IL-4 in the experimental group was greater.

3) Results for Interleukin-5 (IL-5)

Results for interleukin-5 (IL-5) are shown in FIG. 15. As shown in FIG. 15, the control group was 215.63 ± 5.22 pg / ml, the comparative group was 156.52 ± 4.12 pg / ml, and the experimental group was 145.66 ± 4.52 pg / ml. Both the control and experimental groups showed a significant decrease (p <0.01) compared to the control group, and the reduction of IL-5 in the experimental group was greater.

4) Results for Interleukin-6 (IL-6)

Results for interleukin-6 (IL-6) are shown in FIG. 16. As shown in FIG. 16, the control group was 450.12 ± 4.25 pg / ml, the control group was 256.45 ± 4.75 pg / ml, and the experimental group was 241.54 ± 5.23 pg / ml. Both the control and experimental groups showed a significant decrease (p <0.01) compared to the control group, and the reduction of IL-6 was greater in the experimental group.

5) Results for Immunoglobulin M (IgM)

Results for immunoglobulin M (IgM) are shown in FIG. 17. As shown in FIG. 17, the control group was 585.15 ± 45.58 μg / ml, the comparison group was 325 ± 19.21 μg / ml, and the experimental group was 288 ± 25.25 μg / ml. Both the control and experimental groups showed a significant decrease (p <0.01) compared to the control group, and the reduction of IL-4 in the experimental group was greater.

6) Results for Immunoglobulin G1 (IgG1)

Results for immunoglobulin G1 (IgG1) are shown in FIG. 18. As shown in FIG. 18, the control group was 2,784 ± 255.85 μg / ml, the comparison group was 1,958 ± 125.25 μg / ml, and the experimental group was 1,754 ± 165.73 μg / ml. Both control and experimental groups showed a significant decrease (p <0.01) compared to the control group, and the decrease of IgG1 in the experimental group was greater.

7) Results for Interferon-gamma (IFN-γ)

Results for interferon gamma (IFN-γ) are shown in FIG. 19. As shown in FIG. 19, the control group was 815.15 ± 58.52 pg / ml, the comparison group was 1,158 ± 85.65 pg / ml, and the experimental group was 1,298 ± 128.54 pg / ml. Both the control and experimental groups showed a significant increase (p <0.01) compared to the control group, and the IFN-γ increase in the experimental group was greater. Interferon gamma is particularly well known as an anticancer substance.

5. Formulation  Produce

According to the conventional functional food (health functional food) manufacturing method by mixing the following ingredients to produce a health functional food of various formulations. The composition ratio of the following vitamin and mineral mixtures was formulated as an example of the formulation based on the nutritional recommended amount of a relatively suitable component for health functional food, but may be carried out by modifying the formulation ratio arbitrarily.

<Formulation Example 1> Drink

The following amount of the component was passed through a filter having a diameter of 2-3 μm, and the final mixture was clarified at 90-93 ° C. for 15-20 seconds to be sterilized in a 50 ml bottle, followed by 15-20 minutes at 80-85 ° C. Sterilization to prepare a beverage product (50ml).

Ingredients Content (unit: mg)
Drinks1 Example 1 Extract
Hyaluronic acid
Collagen Peptides
Vitamin C
Vitamin B ₂
Vitamin B ₆
Dietary Fiber
Pomegranate Extract
Liquid fructose
Purified water 1,000
75
75
75
4
3
1,000
8,000
20,000
Suitable amount
Drinks2 Example 1 Extract
Citric acid
oligosaccharide
Taurine
Purified water 1000 mg
1000mg
100 g
1g
Suitable amount

<Formulation Example 2> Tablet

The following amounts of ingredients are mixed and kneaded to produce granules through a granulation machine, and then 5 mg of magnesium stearate is mixed and evenly mixed and compressed into tablets to produce a tablet.

Ingredients Content (unit: mg) Example 1 Extract
Hyaluronic acid
Collagen Peptides
Vitamin C
Vitamin B2
Vitamin B6
Dietary Fiber
Lactose
Lacchuros
Spices 1,000
75
75
75
4
3
100
200
260
30

<Formulation Example 3> soft capsule

The following amount of material is mixed, homogenized and prepared by filling into a soft capsule of constant weight according to a conventional method.

Ingredients Content (unit: mg) Example 1 Extract
Hyaluronic acid
Collagen Peptides
Vitamin C
Vitamin B2
Vitamin B6
Tocopherol
Dietary Fiber
Wheat germ oil
Wax
Wax 1,000
75
75
75
4
3
50
100
3.500
500
500

<Formulation Example 4> Granules

The following amounts of materials are mixed and kneaded to produce granules through a granulator.

Ingredients Content (unit: mg) Example 1 Extract
Hyaluronic acid
Collagen Peptides
Vitamin C
Vitamin B2
Vitamin B6
Dietary Fiber
Lactose
Lacchuros
Spices 1,000
75
75
75
4
3
100
200
260
30

<Formulation Example 5> Powder

The powder of the following amount is mixed and a powder is manufactured using a conventional manufacturing method.

Ingredients content Example 1 Extract
Vitamin A Acetate
Vitamin E
Vitamin B1
Vitamin B2
Vitamin B6
Niacin
Folic acid
Ferrous sulfate
Zinc oxide
Magnesium carbonate
Calcium phosphate
Potassium citrate
Magnesium chloride 1,000mg
70 µg
1mg
0.2mg
0.2mg
0.2mg
20mgNE
50 µg
2mg
1mg
20mg
100mg
100mg
25mg

<Formulation Example 6> Syrup

The following amounts of materials are mixed to prepare syrups using conventional manufacturing methods.

Ingredients content Example 1 Extract
Starch sodium glycolate
Hydroxypropylmethylcellulose
Xanthan Gum
D-mannitol
Refined sugar
Citric acid
Sodium citrate 0.2mg
1.4mg
3.2mg
0.3mg
50 mg
142mg
0.3mg
0.5mg

<Formulation Example 7> Gum

The following amounts of ingredients are mixed and kneaded to prepare a gum in a conventional manner.

Ingredients Content (unit: weight%) Example 1 Extract
Gum base
Sugar
Spices
water 5
20
72
One
2

Formulation Example 8 Biscuits

The following amounts of ingredients are mixed and kneaded to prepare biscuits in a conventional manner.

Ingredients Content (unit: weight%) Example 1 Extract
Force Level 1
Gravity Class I
White sugar
saline
glucose
Palm Shortening
baking soda
Sodium bisulfite
Rice flour
Vitamin B1
Vitamin B2
Milk flavor
water
Whole milk powder
Substitute powdered milk
Calcium Phosphate
Spreading salt
Spray oil 5.00
21.59
22.22
4.80
0.73
0.78
11.15
0.17
0.16
1.45
0.0001
0.0001
0.04
21.33
1.16
0.29
0.03
0.29
7.27

While the present invention has been particularly shown and described with reference to specific embodiments thereof, those skilled in the art will appreciate that such specific embodiments are merely preferred embodiments and that the scope of the present invention is not limited thereby. something to do. It is therefore intended that the scope of the invention be defined by the claims appended hereto and their equivalents.

Claims (10)

Health functional food composition for improving skin diseases comprising a mixed extract of mammundong, ginseng, Schisandra chinensis and Eoseongcho.
The method of claim 1,
The mixed extract is at least one selected from crude extract, dried crude extract, crude extract concentrate, crude extract fraction, dried fraction and concentrate of fractions of the health functional food composition for improving skin diseases.
The method of claim 1,
The mixed extract is the weight ratio of Macmundong: ginseng: Schisandra chinensis: eoseongcho is 1 to 8: 1 to 4: 1 to 4: 1 to 8, characterized in that the health functional food composition for improving skin diseases.
The method of claim 1,
The mixed extract is Macmundong: ginseng: Schisandra chinensis: Eoseongcho weight ratio of 1: 1: 1: 2, the health functional food composition for improving skin diseases.
The method of claim 1,
The mixed extract is a health functional food composition for improving skin diseases, characterized in that the extract available in a solvent selected from water, lower alcohols having 1 to 4 carbon atoms or a mixed solvent thereof.
The method according to any one of claims 1 to 5,
The health functional food composition for improving skin diseases is further formulated as one formulation selected from the group consisting of tablets, pills, powders, granules, powders, capsules and liquid formulations further comprising one or more of carriers, diluents, excipients and additives. Health functional food composition for improving the skin disease, characterized in that.
Adding and extracting a solvent selected from water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof to mungmundong, ginseng, Schisandra chinensis and Eochochoea to obtain a mixed extract; And
Method for producing a health functional food composition for improving skin diseases comprising the step of concentrating the mixed extract.
The method of claim 7, wherein
The step of obtaining the mixed extract is a method for producing a health functional food composition for improving skin diseases, characterized in that the extract by adding a solvent of 5 to 20 times the weight of the total weight of ganmundong, ginseng, Schisandra chinensis and eoseongcho.
The method of claim 7, wherein
Obtaining the mixed extract is a method for producing a health functional food composition for improving skin diseases, characterized in that performed for 1 hour to 10 hours at 80 ℃ to 120 ℃.
The method of claim 7, wherein
Concentrating the mixed extract comprises filtering the extract, concentrating the filtered extract under reduced pressure, drying the concentrated extract and pulverizing the dried concentrate to powder Method for producing a health functional food composition for improving skin diseases.

Images